Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial
BVd demonstrated manageable safety and clinical activity across all dosing cohorts in heavily pretreated RRMM, supporting the 2.5 mg/kg Q3W dose.
Authors
- Astrid McKeown (ORCID: https://orcid.org/0009-0007-7240-4708)
- Ravi S. Kasinathan
- Amit Khot (ORCID: https://orcid.org/0000-0002-9210-5373)
- N. Patel
- J. Opalinska
- Mehreen Shaikh
- Rachel Rogers (ORCID: https://orcid.org/0000-0003-0810-1714)
- Bradley Augustson
- Paul Cannell
- Andrew Spencer
- Sumita Roy-Ghanta
- Keith Stockerl-Goldstein
- Amy Curry
- Fernando Carreno
- Hang Quach
- Ajay Nooka
- Rakesh Popat
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- Emory University (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Washington University in St. Louis (US)
- Age UK (GB)
- Peter MacCallum Cancer Centre (AU)
- Fiona Stanley Hospital (AU)
- Sir Charles Gairdner Hospital (AU)
- National Institute for Health and Care Research (GB)
- St Vincent's Hospital Melbourne (AU)
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (Poland) (PL)
- GlaxoSmithKline (Germany) (DE)
- University College London (GB)
- Monash University (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3216
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Seagen